Catalytic therapy of cancer by ascorbic acid involves redox cycling of exogenous/endogenous copper ions and generation of reactive oxygen species

Chemotherapy

Volumn 56, Issue 4, 2010, Pages 280-284

  Hadi, S M ^a   Ullah, M F ^a   Shamim, U ^a   Bhatt, S H ^b   Azmi, A S ^c  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Ascorbate; Cancer; Catalytic therapy; Comet assay; Copper; Oxidative DNA breakage; Polyphenol antioxidants; Prooxidants

Indexed keywords

2,9 DIMETHYL 1,10 PHENANTHROLINE; ASCORBIC ACID; CELL DNA; COPPER ION; CUPRIC ION; CUPROUS ION; POLYPHENOL; REACTIVE OXYGEN METABOLITE;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CANCER CELL; CANCER THERAPY; CATALYSIS; CELLULAR DISTRIBUTION; CHROMATIN; COMET ASSAY; COPPER BLOOD LEVEL; CYTOTOXICITY; DNA CLEAVAGE; DNA DEGRADATION; DNA STRAND BREAKAGE; HUMAN; IN VITRO STUDY; LYMPHOCYTE; OXIDATION; PRIORITY JOURNAL; REVIEW; TISSUE DISTRIBUTION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIOXIDANTS; ASCORBIC ACID; COPPER; DNA BREAKS; DNA CLEAVAGE; FLAVONOIDS; HUMANS; LYMPHOCYTES; NEOPLASMS; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES;

EID: 77955547212     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319951     Document Type: Review

References (38)

1. Rozanava N, Zhang JZ, Heck DE: Catalytic therapy of cancer with porphyrins and ascorbate. Cancer Lett 2007; 18: 216-224.
2. Dikalov SI, Vitek MP, Mason RP: Cupric amyloid beta peptide complex stimulated oxidation of ascorbate and generation of hydroxyl radical. Free Radic Biol Med 2004; 36: 340-347.
3. Ahmad MS, Fazal F, Rahman A, Hadi SM, Parish JH: Activities of flavonoids for the cleavage of DNA in the presence of Cu(II): correlation with the generation of active oxygen species. Carcinogenesis 1992; 13: 605-608.
4. Hanif S, Shamim U, Ullah MF, Azmi AS, Bhatt SH, Hadi SM: The anthocyanidin delphinidin mobilizes endogenous copper ions from human lymphocytes leading to oxidative degradation of cellular DNA. Toxicology 2008; 249: 19-25.
5. Aggarwal BB, Bhardwaj A, Aggarwal RS, et al: Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004; 24: 2783-2840.
6. Bhat SH, Azmi AS, Hanif S, Hadi SM: Ascorbic acid mobilizes endogenous copper in human peripheral lymphocytes leading to oxidative DNA breakage: a putative mechanism for anticancer properties. Int J Biochem Cell Biol 2006; 38: 2074-2081.
7. Azmi AS, Bhat SH, Hadi SM: Resveratrol- Cu(II) induced DNA breakage in human peripheral lymphocytes: implications for anticancer properties. FEBS Lett 2005; 579: 3131-3135.
8. Podmore ID, Griffith HR, Herbert KE, Mistry N, Mistry P, Lunec J: Vitamin C exhibits pro-oxidant properties. Nature 1998; 395: 231-232.
9. Schumacker PT: Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 2006; 10: 175-176.
10. Yoshikawa T, Tainaka K, Naito Y, Kondo M: A novel cancer therapy based on oxygen radicals. Cancer Res 1995; 55: 1617-1620.
11. Kimoto EH, Tanaka J, Gytoku F, Morishige F, Pauling L: Enhancement of antitumor activity of ascorbate against Ehrlich ascites tumor cells by copper: glycylglycylhistidine complex. Cancer Res 1983; 43: 824-828.
12. Cameron E, Pauling L, Leibovitz B: Ascorbic acid and cancer: a review. Cancer Res 1979; 39: 663-681.
13. Gupte A, Mumper RJ: Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev 2008; 35: 32-46.
14. Singh NP: Sodium ascorbate induces DNA single-strand breaks in human cells in vitro. Mutat Res 1997; 375: 195-203.
15. Sakagami H, Satoh K: Modulating factors of radical intensity and cytotoxic action of ascorbate. Anticancer Res 1997; 17: 3513-3520.
16. Rahman A, Shahabuddin A, Hadi SM, Parish JH: Complexes involving quercetin, DNA and Cu(II). Carcinogenesis 1990; 11: 2001-2003.
17. Ehrenfeld GM, Shipley JB, Heimbrook DC, et al: Copper dependent cleavage of DNA by bleomycin. Biochemistry 1987; 26: 931-942.
18. Bryan SE: Metal Ions in Biological Systems. New York, Marcel Dekker, 1979.
19. Burkitt MJ, Milne L, Nicotera P, Orrenius S: 1,10-Phenanthroline stimulates internucleosomal DNA fragmentation in isolated rat liver nuclei by promoting redox activity of endogenous copper ions. Biochem J 1996; 313: 163-169.
20. Malik A, Azam S, Hadi N, Hadi SM: DNA degradation by water extract of green tea in the presence of copper ions: implications for anticancer properties. Phytother Res 2003; 17: 358-363.
21. Wang Y, Ness BV: Site-specific cleavage of supercoiled DNA by ascorbate/Cu(II). Nucleic Acid Res.1989; 17: 6915-6926.
22. Zimmer C, Luck G, Fritzsche H, Triebel H: DNA-copper (II) complex and the DNA conformation. Biopolymers 1971; 10: 441-463.
23. Ullah MF, Khan HY, Zubair H, Shamim U, Hadi SM: The antioxidant ascorbic acid mobilizes nuclear copper leading to a prooxidant cellular DNA breakage: implications for chemotherapeutic action against cancer. Cancer Chemother Pharmacol 2010, E-pub ahead of print.
24. Barbouti A, Doulias PE, Zhu BZ, Frei B, Galaris D: Intracellular iron but not copper plays a critical role in hydrogen-peroxide induced DNA damage. Free Radic Biol Med 2001; 31: 490-498.
25. Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: re-evaluation of prolongation of survival times in terminal human cancers. Proc Natl Acad Sci USA1978; 75: 4538-4542.
26. Creagen ET, Moertal CG, O'Fallon JR, et al: Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 1979; 301: 687-690.
27. Moertal CG, Fleming TR, Creagen ET, Rubin AJ, O'Connell MJ, Ames MM: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double blind comparison. N Engl J Med 1985; 312: 137-141.
28. Riordan NH, Riordan HD, Meng X, Li Y, Jackson JA: Intravenous ascorbate as tumor cytotoxic and tumor therapeutic agent. Med Hypoth 1995; 44: 207-213.
29. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J, Levine M: Pharmacologic doses of ascorbate act as a prooxidant and decrease growth aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 2008; 105: 11105-11109.
30. Omaye TS, Skala JH, Jacob RA: Plasma ascorbic acid in adult males: effects of depletions and supplementation. Am J Clin Nutr 1986; 44: 257-264.
31. Padayatty SJ, Sun H, Wang Y, et al: Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 2004; 140: 533-538.
32. Linder MC: Nutritional Biochemistry and Metabolism. New York, Elsevier Science, 1991.
33. Ebadi E, Swanson S: The status of copper, zinc and metallothionein in cancer patients. Prog Clin Biol Res 1988; 259: 167-175.
34. Yoshida D, Ikada Y, Nakayama S: Quantitative analysis of copper, zinc and copper/zinc ratios in selective human brain tumors. J Neurooncol 1993; 16: 109-115.
35. Smets KA: Programmed cells death (apoptosis) and the response to anticancer drugs. Anticancer Drugs 1994; 5: 3-9.
36. Pryor WA: Why is hydroxyl radical the only radical that commonly binds to DNA? Hypothesis: it has rare combination of high electrophilicity, thermochemical reactivity and a mode of production near DNA. Free Radic Biol Med 1988; 4: 219-233.
37. Chevion M: Site-specific mechanism for free radical induced biological damage. The essential role of redox-active transition metals. Free Radic Biol Med 1988; 5: 27-37.
38. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Schacter E, Levine M: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 2005; 102: 13604-13609.